Cite
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
MLA
Buijs, Manon, et al. “Phase 2 Trial of Concurrent Bevacizumab and Transhepatic Arterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma.” Cancer, vol. 119, no. 5, Mar. 2013, pp. 1042–49. EBSCOhost, https://doi.org/10.1002/cncr.27859.
APA
Buijs, M., Reyes, D. K., Pawlik, T. M., Blackford, A. L., Salem, R., Messersmith, W. A., Weekes, C. D., Mulcahy, M., Kamel, I. R., & Geschwind, J.-F. H. (2013). Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer, 119(5), 1042–1049. https://doi.org/10.1002/cncr.27859
Chicago
Buijs, Manon, Diane K Reyes, Timothy M Pawlik, Amanda L Blackford, Riad Salem, Wells A Messersmith, Colin D Weekes, Mary Mulcahy, Ihab R Kamel, and Jean-Francois H Geschwind. 2013. “Phase 2 Trial of Concurrent Bevacizumab and Transhepatic Arterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma.” Cancer 119 (5): 1042–49. doi:10.1002/cncr.27859.